JLABS @ NYC: Meet With…FundRx
10:30 AM — 1:00 PM
Zeshan Muhammedi, Gurdane Bhutani, and Autri Chattopadhyay of the FundRx team will give an overview presentation about their company’s key areas of interest.
FundRx is a New York based venture capital firm that invests in high impact healthcare and life science startups. On February 8th, Zeshan Muhammedi, Gurdane Bhutani, and Autri Chattopadhyay of the FundRx team will be in attendance to give an overview presentation about their company’s key areas of interest and to meet 1-on-1 with companies that have been accepted after applying online.
FundRx believes deeply in supporting entrepreneurs, and has a community of hundreds of physicians, scientists, and industry advisors who are available to support, mentor, and co-invest into its portfolio companies. Learn more at FundRx.com.
Within healthcare, FundRx is sector agnostic and looks at opportunities across the following industries: -Biotechnology
10:30 AM | Registration Opens and Networking
11:00 AM | Presentation and Q&A
12:00 PM | Networking Lunch
1:00-5:00 PM | One-on-One Meetings*
*Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due January 22, 2018.
Presentation & Lunch
$25 | General Public
$35 | At the door
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on February 7th (or sold out).
FREE | Application
FREE | Accepted Companies
Companies must apply for a one-on-one meeting ahead of time. The one-on-one application period will close on January 22nd, 2018. Your application will be reviewed and you will be notified of acceptance by January 31st, 2018. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.
New York Genome Center
101 Avenue of the Americas
(1st Floor Auditorium)
New York, NY 10013
Zeshan Muhammedi | CEO, FundRx
Mr. Muhammedi is a founder of FundRx and serves as its CEO. Mr. Muhammedi is a serial entrepreneur, having previously held senior management positions at four startup ventures. Most recently, he led business development efforts for AVARX, a healthcare M&A database and technology platform built by Torreya Partners, a leading boutique healthcare investment bank.
To learn more about Mr. Zeshan Muhammedi, click this link.
Gurdane Bhutani | Managing Partner, FundRx
Mr. Bhutani is a founder and Managing Partner at FundRx. Prior to FundRx, he worked in the New York office of Bain & Company as a consultant to clients across the private equity and technology industries. Previously, he worked in the public finance group at Morgan Stanley and at StartUpHealth.
To learn more about Mr. Gurdane Bhutani, click this link.
Autri Chattopadhyay | Director, FundRx
Mr. Chattopadhyay is a Director at FundRx. Previously, he was an associate in Huron’s Life Sciences Strategy practice (legacy Frankel Group) where he worked on a wide range of commercial projects for pharmaceutical and biotechnology companies.
To learn more about Mr. Autri Chattopadhyay, click this link.
About the Meet With… Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, Mercury Fund, DARPA’s Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCI, NCATS, NINDS, Allegory Venture Partners, Clarus Ventures, Johnson & Johnson Innovation, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.
+FIVE POINTSFive Points lecture series bring leading scientists from around the world for an in-depth discussion of their work with students, researchers and clinicians from the New York Genome Center, its member institutions, and others in the medical/scientific community. While Five Points lectures are free and open to the general public, these lectures are most beneficial to scientists, clinicians and researchers who wish to accelerate their research through the use of DNA sequencing technology and bioinformatics. Five Points lectures often frame five or so key points, in a nod to the series’ name — followed by 15 minutes of Q&A, and 30 minutes of networking over hors d’oeuvres and cocktails. These afternoon events are held in the Center’s state-of-the-art ground-floor auditorium starting at 4 pm.
+EVENING TALKSThe New York Genome Center’s Evening Talks events feature distinguished experts from around the world sharing genomic insights and research. They are intended to showcase and explain high science to the non-scientific community. Speakers present the latest research findings and explain its implication for helping improve clinical care for a wide array of serious diseases. The lecture is followed by a lively question-and-answer session and a post-event reception of hors d’oeuvres and cocktails. These popular free public events are held in the Center’s state-of-the-art ground-floor auditorium starting at 6:30 pm. The Evening Talks Series is sponsored by The New York Community Trust – Pyewacket Fund.
+New York Cancer Genomics Research NetworkTo advance collaborative efforts on cancer genomics, the New York Genome Center (NYGC) hosts meetings on the first Tuesday of every month to bring together leading cancer researchers, clinicians and postdocs from the NYGC’s Institutional Founding Members and other key academic institutions. The organizers include Drs. Harold Varmus (Weill Cornell Medicine & NYGC), Marcin Imielinski (Weill Cornell Medicine & NYGC), Ross Levine (Memorial Sloan Kettering Cancer Center) and Sohail Tavazoie (The Rockefeller University).